SHR-1701 + famitinib

SHR-1701 + famitinib is a combination regimen composed of **SHR-1701**, a bifunctional fusion protein targeting both PD-L1 (Programmed death-ligand 1) and TGF-β (Transforming growth factor beta) pathways, and **famitinib**, an oral small molecule multi-targeted receptor tyrosine kinase inhibitor. SHR-1701 is engineered by fusing a monoclonal antibody against PD-L1 to the extracellular domain of TGF-β receptor II, blocking both immune checkpoint and TGF-β signaling to enhance antitumor immunity. Famitinib targets several tyrosine kinases, including VEGFR2/3, PDGFR, c-Kit, and Flt1/3, inhibiting tumor angiogenesis and tumor cell proliferation. Used together, these drugs aim to overcome resistance to checkpoint inhibitors and target both the tumor microenvironment and angiogenesis. The combination has been evaluated in clinical trials for refractory advanced biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC), among other solid tumors[1][2][3][4][5][6].